ID   NOZ
AC   CVCL_3079
SY   NOZAWA; NOZC-1
DR   BioGRID_ORCS_Cell_line; 1160
DR   BioSample; SAMN03472480
DR   cancercelllines; CVCL_3079
DR   Cell_Model_Passport; SIDM01812
DR   Cosmic; 1122352
DR   Cosmic; 2629294
DR   Cosmic; 2674061
DR   DepMap; ACH-001607
DR   JCRB; JCRB1033
DR   JCRB; NIHS0283
DR   Wikidata; Q54930937
RX   CelloPub=CLPUB00469;
RX   DOI=10.1007/BF02348185;
RX   PubMed=2543327;
RX   PubMed=3154020;
RX   PubMed=32293552;
RX   PubMed=32899426;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: 40-48 hours (CelloPub=CLPUB00469); 30 hours (PubMed=32293552); 48 hours (PubMed=3154020); 30 hours (Note=Lot 09162008) (JCRB=JCRB1033).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Unspecified (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: NO2; Cosmic=2629294.
CC   Discontinued: JCRB; NIHS0283; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DepMap; JCRB
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 8,12
ST   D16S539: 9,11
ST   D18S51: 12
ST   D21S11: 30,31
ST   D3S1358: 15,17
ST   D5S818: 11,13
ST   D7S820: 10,11
ST   D8S1179: 9,14
ST   FGA: 17
ST   Penta D: 11,13
ST   Penta E: 12,17
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 19
DI   NCIt; C3844; Gallbladder carcinoma
DI   ORDO; Orphanet_56044; Carcinoma of gallbladder and extrahepatic biliary tract
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 26
//
RX   CelloPub=CLPUB00469;
RA   Homma S.;
RT   "Studies on the establishment and some biological characteristics of
RT   cultured human liver cancer cell lines. Their growth, functional and
RT   morphological characteristics and temperature sensitivities.";
RL   Jikeikai Med. J. 32:289-315(1985).
//
RX   DOI=10.1007/BF02348185;
RA   Kawada M., Aizaki H., Fukaya K.-i., Niiya M., Matsuura T., Sujino H.,
RA   Hasumura S., Nagamori S., Toda G.;
RT   "Morphological changes in human gall bladder carcinoma cell line-NOZ
RT   due to epirubicin and doxorubicin.";
RL   Med. Electron Microsc. 27:175-177(1994).
//
RX   PubMed=2543327;
RA   Hasumura S., Nagamori S., Fujise K., Homma S., Sujino H., Matsuura T.,
RA   Shimizu K., Niiya M., Kameda H.;
RT   "Combination therapy of hyperthermia and other methods in liver and
RT   bile tract cancers -- evaluation of these methods using cancer cell
RT   lines in vitro.";
RL   Gan To Kagaku Ryoho 16:1905-1912(1989).
//
RX   PubMed=3154020;
RA   Homma S., Hasumura S., Nagamori S., Kameda H.;
RT   "Establishment and characterization of a human gall bladder carcinoma
RT   cell line NOZ.";
RL   Hum. Cell 1:95-97(1988).
//
RX   PubMed=32293552; DOI=10.1186/s40659-020-00282-7;
RA   Garcia P., Bizama C., Rosa L., Espinoza J.A., Weber H.,
RA   Cerda-Infante J., Sanchez M., Montecinos V.P., Lorenzo-Bermejo J.,
RA   Boekstegers F., Davila-Lopez M., Alfaro F., Leiva-Acevedo C.,
RA   Parra Z., Romero D., Kato S., Leal P., Lagos M., Roa J.C.;
RT   "Functional and genomic characterization of three novel cell lines
RT   derived from a metastatic gallbladder cancer tumor.";
RL   Biol. Res. 53:13.1-13.17(2020).
//
RX   PubMed=32899426; DOI=10.3390/cancers12092510;
RA   Scherer D., Davila Lopez M., Goeppert B., Abrahamsson S.,
RA   Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D.,
RA   Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.;
RT   "RNA sequencing of hepatobiliary cancer cell lines: data and
RT   applications to mutational and transcriptomic profiling.";
RL   Cancers (Basel) 12:2510.1-2510.14(2020).
//